Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788269 | PMC |
| http://dx.doi.org/10.1136/ejhpharm-2019-002026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a novel tool for individual treatment trials in mucopolysaccharidosis.
J Inherit Metab Dis
January 2025
Institute of Congenital Metabolic Diseases, Paracelsus Medical University, Salzburg, Austria.
Mucopolysaccharidosis (MPS) encompasses a group of genetic lysosomal storage disorders, linked to reduced life expectancy and a significant lack of effective treatment options. Immunomodulatory drugs could have the potential to be a relevant medical approach, as the accumulation of undegraded substances initiates an innate immune response, which leads to inflammation and clinical deterioration. However, immunomodulators are not licensed for this indication.
View Article and Find Full Text PDFManagement and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
Curr Hematol Malig Rep
October 2021
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Purpose Of Review: Despite recent advances in the treatment of de novo acute myeloid leukemia (AML), AML arising from antecedent chronic myelomonocytic leukemia (CMML) continues to have dismal outcomes. While the unique biological drivers of CMML and subsequent leukemic transformation (LT) have been revealed with advances in molecular characterization, this has not yet translated to the bedside. Here, we review these biologic drivers, outcomes with current therapies, and rationale avenues of future investigation specifically in blast phase CMML (CMML-BP).
View Article and Find Full Text PDFRNR inhibitor binding studies of : insights from molecular modeling, docking, and simulation studies.
J Biomol Struct Dyn
December 2022
Department of Biotechnology, Siddaganga Institute of Technology, Tumkur, Karnataka, India.
is the primary cause of chronic conjunctivitis without respiratory infections in cats, making conjunctiva as its primary target. It is a Gram-negative obligate intracellular bacterium that cannot survive outside the host cell. can be found worldwide and its zoonotic potential is a known phenomenon.
View Article and Find Full Text PDFThe tumor therapy landscape of synthetic lethality.
Nat Commun
February 2021
Translational Medical Center for Stem Cell Therapy and Institute for Regenerative Medicine, Shanghai East Hospital, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Synthetic lethality is emerging as an important cancer therapeutic paradigm, while the comprehensive selective treatment opportunities for various tumors have not yet been explored. We develop the Synthetic Lethality Knowledge Graph (SLKG), presenting the tumor therapy landscape of synthetic lethality (SL) and synthetic dosage lethality (SDL). SLKG integrates the large-scale entity of different tumors, drugs and drug targets by exploring a comprehensive set of SL and SDL pairs.
View Article and Find Full Text PDFDEEPScreen: high performance drug-target interaction prediction with convolutional neural networks using 2-D structural compound representations.
Chem Sci
March 2020
Department of Computer Engineering , Hacettepe University, Ankara , 06800 , Turkey . Email: ; Tel: +903122977193/117.
The identification of physical interactions between drug candidate compounds and target biomolecules is an important process in drug discovery. Since conventional screening procedures are expensive and time consuming, computational approaches are employed to provide aid by automatically predicting novel drug-target interactions (DTIs). In this study, we propose a large-scale DTI prediction system, DEEPScreen, for early stage drug discovery, using deep convolutional neural networks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!